Pharmaceuticals

New Peer-Reviewed Study Confirms Innovative Technology Shatters ESR's Four-Hour Deadline

ALCOR Scientific's iSED® analyzers reshape lab logistics and improve patient care for one of medicine's most widely used tests * Seven times longer stability, independently validated. ESR samples on ALCOR Scientific's iSED analyzer remained accurate for up to 28 hours at room temperature and 4...

2026-09-17 21:00 1906

There's No One-Size-Fits-All for Treating Older Adults with Cancer, According to New NCCN Patient Resource

New guideline for patients and caregivers explains the importance of assessments to tailor cancer care to every person, regardless of age. PLYMOUTH MEETING, Pa., Sept. 17, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—is publ...

2026-09-17 20:20 1439

Clarivate Reveals Citation Laureates 2026 Recognizing Transformative Scientific Breakthroughs

22 researchers honored for Nobel-class discoveries, including pioneers of GLP-1 medicines and other world-changing advances LONDON, Sept. 17, 2026 /PRNewswire/ -- Clarivate Plc ...

2026-09-17 15:05 1627

Tianjin University Leads World's 1st ISO Standard for Single-Herb TCM Formula Granules

TIANJIN, China, Sept. 16, 2026 /PRNewswire/ -- The International Organization for Standardization (ISO) has published ISO 21756:2026, the world's first international standard for single-herb Traditional Chinese Medicine (TCM) formula granules. Titled Traditional Chinese Medicine —Salvia miltiorrh...

2026-09-17 13:25 2108

OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody

* Cesalatamig is Currently Being Evaluated in Phase 1/2 Studies in the United States (NCT06635785 ) and in China (CTR20253261

2026-09-16 19:00 2169

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

* Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW) * Eptinezumab is the only intravenous (IV) CGRP-targeted preventive treatment approved for the prevention of migraine attacks in adults and launched in over 30 countries worldwide * Authorization supported by the Pha...

2026-09-16 14:28 2086

Skyhawk Therapeutics Announces Final Fifteen-Month Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease Patients

* The fifteen-month dataset represents the final analysis from the Phase 1/2 study * At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington's Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted extern...

2026-09-16 00:58 2746

CordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of Growth

* Dr. Jean-Luc Herbeaux appointed Chief Executive Officer of CordenPharma, effective 1 October 2026   * Dr. Michael Quirmbach to transition from President & CEO to Board Member and Senior Advisor, remaining actively involved with CordenPharma   * Planned leadership transition builds on 12 ye...

2026-09-15 22:30 2582

5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) Officially Opens

HONG KONG, Sept. 11, 2026 /PRNewswire/ -- Hong Kong International Biotechnology Conference and Exhibition (BIOHK2026) officially opened on September 9, 2026, at the Hong Kong Convention and Exhibition Centre. Marking a key 5-year milestone, this flagship life sciences event connects Hong Kong, Ma...

2026-09-15 13:58 1599

Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO

CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced thatresults from the phase III registrational study of its novel human epidermal growth factor receptor 2 (HER2)-targeted antibody–drug conjugate...

2026-09-14 14:33 2060

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...

2026-09-14 12:38 1910

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

* Pixclara® is the first FDA-approved FET-PET imaging drug for glioma (brain cancer). * Approval addresses a significant unmet need, helping physicians to differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients. * FET-PET imaging is recom...

2026-09-14 06:56 2501

IonOpticks launches Aurora Series® 5 and new CoreJet™ emitter technology, advancing robust nano-LC for routine proteomics research.

New CoreJet™ integrated emitter technology and a redesigned nanoZero® union combine proven Aurora Series® performance with a step-change in robustness, lowering cost per sample without compromising the depth and sensitivity researchers depend on. MELBOURNE, Australia, Sept. 14, 2026 /PRNewswire/...

2026-09-14 06:30 2624

THE GALIEN FOUNDATION ANNOUNCES INAUGURAL PRIX GALIEN JAPAN FORUM & AWARDS CEREMONY

Prestigious Life Sciences Platform and Awards Launch in Tokyo to Celebrate Breakthrough Innovation TOKYO, Sept. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced that it will host the first Prix Galie...

2026-09-11 08:00 2399

Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults

Phase 3 study demonstrates benefits of the first influenza vaccine to combine three proven approaches to enhancing protection for older adults in a single vaccine. MAIDENHEAD, United Kingdom, Sept. 11, 2026 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced ...

2026-09-11 06:51 3963

ABEC Opens New Manufacturing Facility in Wilson, North Carolina

Grand Opening Ceremony Scheduled for September 24, 2026 BETHLEHEM, Pa., Sept. 10, 2026 /PRNewswire/ -- ABEC, a global leader in customized solutions and services for biopharmaceutical manufacturing, today announced the grand opening of its newest manufacturing facility in Wilson, North Carolina....

2026-09-10 23:11 2291

Dr Hanan H. Balkhy Launches Candidacy for WHO Director-General, Pledges "A WHO the World Can Count On"

* Nominated by the Kingdom of Saudi Arabia * A physician trained in Saudi Arabia and the United States, with more than 30 years of experience spanning clinical medicine, academic research and international public health leadership * WHO Regional Director for the Eastern Mediterranean sets ou...

2026-09-10 20:55 2457

ZEISS announces commercial availability of bitoric hydrophobic monofocal IOL - the ZEISS AT LUCIA toric 721P

Launching at ESCRS in London, the world's first bitoric hydrophobic monofocal intraocular lens with a non-constant asphericity profile design expands the ZEISS LUCIA Family to treat cataracts while simultaneously correcting astigmatism. JENA, Germany, Sept. 10, 2026 /PRNewswire/ -- ZEISS Medical...

2026-09-10 20:00 1959

/C O R R E C T I O N -- CordenPharma/

In the news release, CordenPharma Boosts Aseptic Fill-Finish Capacity to 500 Million Sterile Injectable Units Per Year, issued 10-Sep-2026 by CordenPharma over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details ...

2026-09-10 19:28 2314

First Participant Dosed in First-in-Human Phase 1 Study of GZC8072, a Novel Ultra-Long-Acting Once-Weekly Oral Peptide GLP-1 RA

BEIJING and BRIDGEWATER, Mass., Sept. 9, 2026 /PRNewswire/ -- Gan&Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan&Lee) announced that the first participant has been dosed in a First-In-Human (FIH) Phase 1 study of GZC8072 tablets, a novel ultra-long-acting oral peptide GLP-1 RA form...

2026-09-09 21:00 4357
12345 ... 184

Week's Top Stories